- Paper Report
- Open Access
Tamoxifen may reduce CHD risk via inflammatory mediators
- Joanna Lyford1
© Biomed Central Ltd 2001
- Received: 14 March 2001
- Published: 18 October 2001
- Breast cancer, cardiovascular disease, cholesterol, C-reactive protein, fibrinogen, tamoxifen
Previous breast cancer trials have demonstrated reductions in cardiac death of between 15% and 60% in women treated with tamoxifen. This study investigated whether tamoxifen reduces the levels of inflammatory markers that are linked to an increased risk of heart disease.
Tamoxifen was shown to reduce levels of C-reactive protein by 26% and fibrinogen levels by 22%, as well as a 9% reduction in cholesterol. All of these reductions were significant compared with the effects of placebo (P <0.01). Specific treatment effects were not noted with factor VII coagulant, fragment 1-2, and triglycerides.
The authors studied 111 women previously enrolled in the National Surgical Adjuvant Breast and Bowel Program P-1 trial. The average age of the women was 58 years and most were postmenopausal. Fifty-one women were randomly assigned to receive tamoxifen 20 mg/day and the remainder took placebo. The study period was 6 months.
- Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN: Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001, 21: 225-261. Google Scholar